Pfizer (PFE 37.46, -0.20, -0.5%) will report its Q2 results ahead of tomorrow's opening bell, followed by the management's conference call at 10:00 ET.
The Capital IQ consensus expects the drugmaker to report a 17.5% yr/yr drop in EPS to $0.66 on a 12.9% yr/yr drop in revenue to $11.55 bln.
The company reaffirmed its FY20 guidance for EPS between $2.82 and $2.92 on revenue between $48.50 bln and $50.50 bln when it reported Q1 results on April 28.
TECHS:
Pfizer trades at 14.4x forward earnings expectations, which is a premium to Novartis (NVS 84.80, +0.58, +0.7%), and Merck (MRK 78.39, +1.29, +1.7%), but a discount to Amgen (AMGN 251.40, +3.42, +1.4%) and Eli Lilly (LLY 160.47, +0.93, +0.6%).
If you liked this content please click the ❤️ below and/or share this post.
TOTALLY FREE Trading Packet!
Click here to get my packet that shows you how I traded $600 into $100K FOR FREE.
This packet will explain to you in depth how I trade and how I manage my risk.
I am happy to share this. Just use the code KPAKFRAUD at checkout and you will get it TOTALLY FREE. You will pay absolutely nothing.
SHAMLESS PLUGS
CLICK HERE TO CHECK OUT MY 2020 PREVIEW OPINION PACKET. OVER 140 PAGES OF CONTENT AND INFORMATION AVAILABLE HERE.
Check out the latest episodes on my YouTube above and SoundCloud channel below.